These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

618 related articles for article (PubMed ID: 1673721)

  • 1. Toxicity profiles of disease modifying antirheumatic drugs in rheumatoid arthritis.
    Singh G; Fries JF; Williams CA; Zatarain E; Spitz P; Bloch DA
    J Rheumatol; 1991 Feb; 18(2):188-94. PubMed ID: 1673721
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [Retrospective study of adverse events in patients with rheumatoid arthritis treated with second-line drugs].
    Jiang L; Zhao N; Ni L
    Zhonghua Liu Xing Bing Xue Za Zhi; 2002 Jun; 23(3):213-7. PubMed ID: 12411093
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Longterm combination therapy of refractory and destructive rheumatoid arthritis with methotrexate (MTX) and intramuscular gold or other disease modifying antirheumatic drugs compared to MTX monotherapy.
    Rau R; Schleusser B; Herborn G; Karger T
    J Rheumatol; 1998 Aug; 25(8):1485-92. PubMed ID: 9712088
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Rheumatoid arthritis: a pharmacologic overview.
    Pinals RS
    Am Fam Physician; 1988 Mar; 37(3):145-52. PubMed ID: 2894754
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Disease modifying antirheumatic drugs in early rheumatoid arthritis: a longterm observational study.
    Papadopoulos NG; Alamanos Y; Papadopoulos IA; Tsifetaki N; Voulgari PV; Drosos AA
    J Rheumatol; 2002 Feb; 29(2):261-6. PubMed ID: 11838843
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Variability in individual responses of 532 patients with rheumatoid arthritis to first-line and second-line drugs.
    Pincus T; Callahan LF
    Agents Actions Suppl; 1993; 44():67-75. PubMed ID: 8103964
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Drugs for rheumatoid arthritis.
    Med Lett Drugs Ther; 1989 Jun; 31(795):61-4. PubMed ID: 2567489
    [No Abstract]   [Full Text] [Related]  

  • 8. Adverse events with disease modifying antirheumatic drugs (DMARD): a cohort study of leflunomide compared with other DMARD.
    Cannon GW; Holden WL; Juhaeri J; Dai W; Scarazzini L; Stang P
    J Rheumatol; 2004 Oct; 31(10):1906-11. PubMed ID: 15468352
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Methotrexate, hydroxychloroquine, and intramuscular gold in rheumatoid arthritis: relative area under the curve effectiveness and sequence effects.
    Hurst S; Kallan MJ; Wolfe FJ; Fries JF; Albert DA
    J Rheumatol; 2002 Aug; 29(8):1639-45. PubMed ID: 12180722
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Disappointing longterm results with disease modifying antirheumatic drugs. A practice based study.
    Galindo-Rodriguez G; Aviña-Zubieta JA; Russell AS; Suarez-Almazor ME
    J Rheumatol; 1999 Nov; 26(11):2337-43. PubMed ID: 10555887
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Renal toxicity associated with disease-modifying antirheumatic drugs used for the treatment of rheumatoid arthritis.
    Schiff MH; Whelton A
    Semin Arthritis Rheum; 2000 Dec; 30(3):196-208. PubMed ID: 11124283
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Effectiveness profiles and dose dependent retention of traditional disease modifying antirheumatic drugs for rheumatoid arthritis. An observational study.
    Aletaha D; Smolen JS
    J Rheumatol; 2002 Aug; 29(8):1631-8. PubMed ID: 12180721
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Response-driven combination therapy with conventional disease-modifying antirheumatic drugs can achieve high response rates in early rheumatoid arthritis with minimal glucocorticoid and nonsteroidal anti-inflammatory drug use.
    Proudman SM; Keen HI; Stamp LK; Lee AT; Goldblatt F; Ayres OC; Rischmueller M; James MJ; Hill CL; Caughey GE; Cleland LG
    Semin Arthritis Rheum; 2007 Oct; 37(2):99-111. PubMed ID: 17391739
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Low-dose prednisolone in rheumatoid arthritis: adverse effects of various disease modifying antirheumatic drugs.
    Malysheva OA; Wahle M; Wagner U; Pierer M; Arnold S; Häntzschel H; Baerwald CG
    J Rheumatol; 2008 Jun; 35(6):979-85. PubMed ID: 18412314
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Longterm methotrexate use in rheumatoid arthritis: 12 year followup of 460 patients treated in community practice.
    Wluka A; Buchbinder R; Mylvaganam A; Hall S; Harkness A; Lewis D; Littlejohn GO; Miller MH; Ryan PF
    J Rheumatol; 2000 Aug; 27(8):1864-71. PubMed ID: 10955325
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Slow-acting anti-rheumatic drug therapy for rheumatoid arthritis.
    Clegg DO; Ward JR
    Nurse Pract; 1987 Mar; 12(3):44, 49-52. PubMed ID: 2882451
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Slow acting anti-rheumatic drugs in the treatment of rheumatoid arthritis.
    Kovarsky J
    Tex Med; 1985 Sep; 81(9):35-9. PubMed ID: 3931276
    [No Abstract]   [Full Text] [Related]  

  • 18. Prescribing trends in disease modifying antirheumatic drugs for rheumatoid arthritis: a survey of practicing Canadian rheumatologists.
    Pope JE; Hong P; Koehler BE
    J Rheumatol; 2002 Feb; 29(2):255-60. PubMed ID: 11838842
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Longterm drug therapy for rheumatoid arthritis in seven rheumatology private practices: II. Second line drugs and prednisone.
    Pincus T; Marcum SB; Callahan LF
    J Rheumatol; 1992 Dec; 19(12):1885-94. PubMed ID: 1294735
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Current concepts in clinical therapeutics: disease-modifying drugs for rheumatoid arthritis.
    Pugh MC; Pugh CB
    Clin Pharm; 1987 Jun; 6(6):475-91. PubMed ID: 3319362
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 31.